-
-
WHO recommendations for antiviral use for H1N1 flu; antibiotic use trends for acute respiratory tract infection; denosumab clears FDA Expert Panel; FDA Actions.
-
Obsessive-compulsive disorders have achieved greater visibility in our society with several well-known celebrities such as Howie Mandel and David Beckham with acknowledged cases. Patients may be reluctant to share their symptoms with their primary care physician for fear of being thought crazy. Hopefully today the increased recognition with celebrities and greater media attention to the disorder will resolve this fear and allow patients to become more open with their doctors.
-
Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
-
-
-
Vital exhaustion predicts long-term risk for adverse cardiac events in men and women, independent of established biomedical risk factors.
-
A new three-drug antihypertensive pill, combining an angiotensin II receptor antagonist (olmesartan [OLM]), a calcium channel blocker (amlodipine [AML]), and a thiazide diuretic (hydrochlorothiazide [HCTZ]), has been approved by the FDA. The new combination is marketed by Daiichi Sankyo as Tribenzor.
-
Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
-
In a sample of patients from primary care practice, a single screening question accurately identified drug use.
